Scholarlink

Introduction <p>Non-melanoma skin cancers (NMSCs) are the most common malignancies and Mohs micrographic surgery (MMS) with flap reconstruction is the treatment of choice. This study aims to investigate the effect of bromelain on the healing of skin flaps following MMS for NMSCs.</p> Methods <p>In a single-center, parallel-group, single-blinded randomized clinical trial, 60 patients with NMSC who underwent MMS and flap reconstruction were assigned (1:1) to either an intervention group receiving bromelain (1500 mg/day, Rataheal™) for 15 days postoperatively or a control group receiving standard care alone. The primary outcome was time to suture removal; the early wound healing score (EWHS) was recorded supportively. Secondary outcomes included pain, inflammation, keloid/scar formation, cosmetic satisfaction, and traction quality.</p> Results <p>Baseline characteristics (age: 69.2 ± 13.5 years; 71.7% male; flap size: 116.1 ± 7.0 mm<sup>2</sup>) were analyzed. Bromelain significantly shortened time to suture removal compared with controls (2.6 days, 95% CI: 0.74–4.11; <i>p</i> = 0.006). The EWHS was also significantly improved at the day 7 (7.2 vs. 5, <i>p</i> &lt; 0.001) and day 14 (8.56 vs. 7.3, <i>p</i> = 0.014) of follow up. Other outcomes, including inflammation, pain, and cosmetic satisfaction, showed non-significant trends favoring bromelain. No major complications were reported.</p> Conclusion <p>Bromelain supplementation is associated with earlier postoperative wound healing of skin flaps following MMS for NMSC, leading to 2.6 days earlier suture removal plus improvement in the EWHS without adverse effects. Our findings support the potential of bromelain as a safe and effective adjunct therapy for reconstructive skin cancer surgery.</p> Trial registration <p>Iranian Registry of Clinical Trials (IRCT20240903062943N1|| <a href="https://irct.behdasht.gov.ir/trial/79056">https://irct.behdasht.gov.ir/trial/79056</a>), 2024.10.28, enrollment started after registration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigation of oral bromelain supplementation on the healing of skin flap reconstruction after Mohs micrographic surgery (MMS) for non-melanoma skin cancers (NMSCs)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月14日

查看全文
  • Ehsanollah Rahimi-Movaghar,
  • Amir Ehtemami,
  • Melina Ghaneiyan,
  • Tahmineh Tahouri,
  • Sahand Hedayati Omami,
  • Hila Fahimi

摘要

Introduction

Non-melanoma skin cancers (NMSCs) are the most common malignancies and Mohs micrographic surgery (MMS) with flap reconstruction is the treatment of choice. This study aims to investigate the effect of bromelain on the healing of skin flaps following MMS for NMSCs.

Methods

In a single-center, parallel-group, single-blinded randomized clinical trial, 60 patients with NMSC who underwent MMS and flap reconstruction were assigned (1:1) to either an intervention group receiving bromelain (1500 mg/day, Rataheal™) for 15 days postoperatively or a control group receiving standard care alone. The primary outcome was time to suture removal; the early wound healing score (EWHS) was recorded supportively. Secondary outcomes included pain, inflammation, keloid/scar formation, cosmetic satisfaction, and traction quality.

Results

Baseline characteristics (age: 69.2 ± 13.5 years; 71.7% male; flap size: 116.1 ± 7.0 mm2) were analyzed. Bromelain significantly shortened time to suture removal compared with controls (2.6 days, 95% CI: 0.74–4.11; p = 0.006). The EWHS was also significantly improved at the day 7 (7.2 vs. 5, p < 0.001) and day 14 (8.56 vs. 7.3, p = 0.014) of follow up. Other outcomes, including inflammation, pain, and cosmetic satisfaction, showed non-significant trends favoring bromelain. No major complications were reported.

Conclusion

Bromelain supplementation is associated with earlier postoperative wound healing of skin flaps following MMS for NMSC, leading to 2.6 days earlier suture removal plus improvement in the EWHS without adverse effects. Our findings support the potential of bromelain as a safe and effective adjunct therapy for reconstructive skin cancer surgery.

Trial registration

Iranian Registry of Clinical Trials (IRCT20240903062943N1|| https://irct.behdasht.gov.ir/trial/79056), 2024.10.28, enrollment started after registration.